Elan's Alzheimer's mouse

When an animal model - such as mice transgenic for mutant forms of amyloid precursor protein (APP) that are thought to recapitulate the neuropathology of Alzheimer's disease (AD) - finally yields a promising therapeutic, the concern turns to whether that promise will be upheld in humans. After more than a decade of research, Elan Corp. plc (ELN, Dublin, Ireland) may be in a position to put its model to the ultimate test.

Publishing last week in Nature, ELN researchers found that immunization of mutant APP transgenic